2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023.

Authors :: Perkins RB
Guido RS
Castle PE
Chelmow D
Einstein MH
Garcia F
Huh WK
Kim JJ
Moscicki AB
Nayar R
Saraiya M
Sawaya GF
Wentzensen N
Schiffman M
Source :: Journal of lower genital tract disease [J Low Genit Tract Dis] 2024 Jan 01; Vol. 28 (1), pp. 3-6.
Publication Year :: 2024
Abstract: Abstract: This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.<br />Competing Interests: The following listed authors have conflicts of interest: The other authors have declared they have no conflicts of interest.<br /> (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.)